BMS seeks FDA OK for atazanavir/cobicistat FDC in HIV
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb is seeking the FDA's approval to market a fixed-dose combination (FDC) of atazanavir sulfate with Gilead Sciences' cobicistat as a treatment in combination with other antiretroviral agents for HIV-1 infection.